Wednesday 30 September 2015

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015


Researchmoz added Most up-to-date research on "Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015" to its huge collection of research reports. 

Global Markets Directs, Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015, provides an overview of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)s therapeutic pipeline. 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=359924
 
This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
 
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products 

Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

Browse All Reports in Pharmaceutical Category @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
 
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 6
Therapeutics Development 7
Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 7
Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 8
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 9
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 13
Human Stem Cells Institute 13
Lacer, S.A. 14
Nuo Therapeutics, Inc. 15
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21 

For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948

Metastatic Biliary Tract Cancer - Pipeline Review, H2 2015


Researchmoz added Most up-to-date research on "Metastatic Biliary Tract Cancer - Pipeline Review, H2 2015" to its huge collection of research reports. 

Global Markets Directs, Metastatic Biliary Tract Cancer - Pipeline Review, H2 2015, provides an overview of the Metastatic Biliary Tract Cancers therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Metastatic Biliary Tract Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Biliary Tract Cancer and special features on late-stage and discontinued projects. 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=359945
 
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Biliary Tract Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Biliary Tract Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Biliary Tract Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Biliary Tract Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products 

 
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Biliary Tract Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Biliary Tract Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

Browse All Reports in Pharmaceutical Category @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
 
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Biliary Tract Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Biliary Tract Cancer - Overview 7
Pipeline Products for Metastatic Biliary Tract Cancer - Comparative Analysis 8
Metastatic Biliary Tract Cancer - Therapeutics under Development by Companies 9
Metastatic Biliary Tract Cancer - Pipeline Products Glance 10
Clinical Stage Products 10
Metastatic Biliary Tract Cancer - Products under Development by Companies 11
Metastatic Biliary Tract Cancer - Companies Involved in Therapeutics Development 12
Array BioPharma Inc. 12
AstraZeneca Plc 13
GlaxoSmithKline Plc 14
Novartis AG 15
OncoTherapy Science, Inc. 16
Metastatic Biliary Tract Cancer - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 26
binimetinib - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
OCVC-01 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33 

For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948

Anterior Uveitis - Pipeline Review, H2 2015


Researchmoz added Most up-to-date research on "Anterior Uveitis - Pipeline Review, H2 2015" to its huge collection of research reports. 

Global Markets Directs, Anterior Uveitis - Pipeline Review, H2 2015, provides an overview of the Anterior Uveitiss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anterior Uveitis and special features on late-stage and discontinued projects. 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=359951
 
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

Scope
- The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anterior Uveitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anterior Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anterior Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products 

 
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

Browse All Reports in Pharmaceutical Category @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
 
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Anterior Uveitis - Overview 7
Pipeline Products for Anterior Uveitis - Comparative Analysis 8
Anterior Uveitis - Therapeutics under Development by Companies 9
Anterior Uveitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Anterior Uveitis - Products under Development by Companies 13
Anterior Uveitis - Companies Involved in Therapeutics Development 14
Aciont Inc. 14
Aldeyra Therapeutics, Inc. 15
EyeGate Pharmaceuticals, Inc. 16
Kineta, Inc. 17
Neuroptis Biotech 18
Virogenomics, Inc. 19
XOMA Corporation 20
Anterior Uveitis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
dalazatide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30 

For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948

Gastrointestinal Radiation Toxicity - Pipeline Review, H2 2015 Key Trends, Size, Growth, Shares And Forecast


Researchmoz added Most up-to-date research on "Gastrointestinal Radiation Toxicity - Pipeline Review, H2 2015" to its huge collection of research reports.
 
Global Markets Directs, Gastrointestinal Radiation Toxicity - Pipeline Review, H2 2015, provides an overview of the Gastrointestinal Radiation Toxicitys therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Gastrointestinal Radiation Toxicity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Radiation Toxicity and special features on late-stage and discontinued projects. 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=359954
 
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

Scope
- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Radiation Toxicity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastrointestinal Radiation Toxicity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastrointestinal Radiation Toxicity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastrointestinal Radiation Toxicity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products 

 
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Radiation Toxicity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Radiation Toxicity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

Browse All Reports in Pharmaceutical Category @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
 
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastrointestinal Radiation Toxicity Overview 6
Therapeutics Development 7
Pipeline Products for Gastrointestinal Radiation Toxicity Overview 7
Gastrointestinal Radiation Toxicity Therapeutics under Development by Companies 8
Gastrointestinal Radiation Toxicity Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Gastrointestinal Radiation Toxicity Products under Development by Companies 11
Gastrointestinal Radiation Toxicity Companies Involved in Therapeutics Development 12
Aeolus Pharmaceuticals, Inc. 12
Avaxia Biologics, Inc. 13
RedHill Biopharma Ltd. 14
Soligenix, Inc. 15
Gastrointestinal Radiation Toxicity Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25 

For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948